- Home
- VERB vs PHGE Comparison
VERB vs PHGE Comparison
Compare VERB & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERB
- PHGE
- Stock Information
- Founded
- VERB 2014
- PHGE 2015
- Country
- VERB United States
- PHGE Israel
- Employees
- VERB N/A
- PHGE N/A
- Industry
- VERB Other Consumer Services
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- VERB Consumer Discretionary
- PHGE Health Care
- Exchange
- VERB Nasdaq
- PHGE Nasdaq
- Market Cap
- VERB 9.6M
- PHGE 11.0M
- IPO Year
- VERB N/A
- PHGE N/A
- Fundamental
- Price
- VERB N/A
- PHGE N/A
- Analyst Decision
- VERB Strong Buy
- PHGE Strong Buy
- Analyst Count
- VERB 1
- PHGE 1
- Target Price
- VERB $62.00
- PHGE $15.00
- AVG Volume (30 Days)
- VERB 26.8K
- PHGE 295.9K
- Earning Date
- VERB 08-13-2025
- PHGE 08-13-2025
- Dividend Yield
- VERB N/A
- PHGE N/A
- EPS Growth
- VERB N/A
- PHGE N/A
- EPS
- VERB N/A
- PHGE N/A
- Revenue
- VERB $2,193,000.00
- PHGE N/A
- Revenue This Year
- VERB $526.82
- PHGE N/A
- Revenue Next Year
- VERB $45.45
- PHGE N/A
- P/E Ratio
- VERB N/A
- PHGE N/A
- Revenue Growth
- VERB 3125.00
- PHGE N/A
- 52 Week Low
- VERB $3.81
- PHGE $0.34
- 52 Week High
- VERB $27.14
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- VERB 62.46
- PHGE 43.34
- Support Level
- VERB $6.61
- PHGE $0.43
- Resistance Level
- VERB $7.32
- PHGE $0.50
- Average True Range (ATR)
- VERB 0.58
- PHGE 0.05
- MACD
- VERB -0.00
- PHGE 0.00
- Stochastic Oscillator
- VERB 91.94
- PHGE 58.82
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).